EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudie

Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

Eliabe S Abreu, Pedro Henrique Reginato, Jorge Ferreira Jasmineiro Pitanga, Pedro Neves Borges, Pierre-Antoine Soret, Christophe Corpechot, Guilherme Grossi Lopes Cançado

Digestive Diseases and Sciences · 2025

DOI: 10.1007/s10620-025-09044-5 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Eliabe S Abreu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. abreu.eliabe@mayo.edu. Hauptthemen laut MEDLINE: Chenodeoxycholic Acid, Fibric Acids, Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Around 40% of patients diagnosed with Primary Biliary Cholangitis (PBC) experience a suboptimal biochemical response to ursodeoxycholic acid (UDCA). AIMS: We aimed to compare fibrates and obeticholic acid (OCA) as add-on second-line therapy and evaluate whether these drugs hold superiority over each other. METHODS: We systematically searched Embase, MEDLINE, and Cochrane CENTRAL for studies comparing fibrates and OCA published by May 6, 2024. A pooled analysis was conducted to evaluate changes in liver biochemistry and response rates based on validated criteria. Data were expressed as mean difference (MD) for continuous outcomes and as Odds Ratio (OR) when binary. RESULTS: We included 883 patients from 4 studies, 468 (53.0%) under UDCA + OCA. Follow-up time ranged from 6 to 12 months. Patients treated with fibrates have similar mean bilirubin post-intervention values (MD 0.11 × upper limit of normal [ULN]; 95% CI - 0.26 to 0.49) compared to OCA. However, fibrates demonstrated superiority over OCA for percentual reduction in ALP compared to baseline (MD 20.13%; 95% CI 11.84-28.41), ALP post-intervention values (MD - 0.59 xULN; 95% CI - 1.02 to - 0.15), and rate of ALP normalization (OR 32.34; 95% CI 14.54-71.92). Patients treated with fibrates also more frequently met Barcelona (OR 4.28; 95% CI 2.26-8.11), POISE (OR 5.48; 95% CI 2.70-11.13), and Paris II (OR 5.88; 95% CI 3.96-8.74) response criteria. CONCLUSION: In patients with PBC and an incomplete response to UDCA, fibrates seem to be associated with greater ALP reduction and achievement of response criteria compared to OCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chenodeoxycholic AcidFibric AcidsLiver Cirrhosis, BiliaryHumansUrsodeoxycholic AcidTreatment OutcomeDrug Therapy, Combination

Stichwörter der Autor:innen

Add-on therapyFibratesObeticholic acidPrimary biliary cholangitis

Substanzen

obeticholic acidChenodeoxycholic AcidFibric AcidsUrsodeoxycholic Acid

Autor:innen und Institutionen

  • Division of Gastroenterology & Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. abreu.eliabe@mayo.edu.
  • Universidade Federal Do Paraná, Curitiba, PR, Brazil.
  • Facultad de Ciencias Médicas, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
  • Universidade Federal Fluminense, Niterói, RJ, Brazil.
  • Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network On Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Inserm…
  • Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

Zitieren

APA

Abreu, E. S., Reginato, P. H., Pitanga, J. F. J., Borges, P. N., Soret, P. A., Corpechot, C., & Cançado, G. G. L. (2025). Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-025-09044-5

Vancouver

Abreu ES, Reginato PH, Pitanga JFJ, Borges PN, Soret PA, Corpechot C, et al. Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-025-09044-5

BibTeX
@article{Abreu2025,
  author = {Abreu, Eliabe S and Reginato, Pedro Henrique and Pitanga, Jorge Ferreira Jasmineiro and Borges, Pedro Neves and Soret, Pierre-Antoine and Corpechot, Christophe and Cançado, Guilherme Grossi Lopes},
  title = {Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis},
  journal = {Digestive Diseases and Sciences},
  year = {2025},
  doi = {10.1007/s10620-025-09044-5}
}
Kostenlos starten →